Statistical analysis plan of PROWESS SHOCK study.
作者信息
Thompson B Taylor, Ranieri V Marco, Finfer Simon, Barie Philip S, Dhainaut Jean-Francois, Douglas Ivor S, Gårdlund Bengt, Marshall John C, Rhodes Andrew
出版信息
Intensive Care Med. 2010 Nov;36(11):1972-3. doi: 10.1007/s00134-010-1977-3. Epub 2010 Aug 6.
Abstract
摘要
相似文献
1
Statistical analysis plan of PROWESS SHOCK study.PROWESS休克研究的统计分析计划。
Intensive Care Med. 2010 Nov;36(11):1972-3. doi: 10.1007/s00134-010-1977-3. Epub 2010 Aug 6.
2
Severe sepsis: are PROWESS and PROWESS-SHOCK trials comparable? A clinical and statistical heterogeneity analysis.严重脓毒症：PROWESS和PROWESS-SHOCK试验具有可比性吗？一项临床和统计学异质性分析。
Crit Care. 2013 Jul 4;17(4):167. doi: 10.1186/cc12752.
3
Drotrecogin alfa (activated) in severe sepsis.重组人活化蛋白C用于严重脓毒症
N Engl J Med. 2006 Jan 5;354(1):94-6; author reply 94-6. doi: 10.1056/NEJMc052759.
4
Drotrecogin alfa (activated) in patients with severe sepsis and a high risk of death.严重脓毒症且死亡风险高的患者使用活化蛋白C。
Crit Care. 2006;10(6):427. doi: 10.1186/cc5117.
5
[Surgical patients with severe sepsis: first results of the PROWESS study. Demographic data].
Ann Fr Anesth Reanim. 2003 Dec;22 Spec No 1:38-9.
6
Treating sepsis.治疗败血症。
N Engl J Med. 2002 Sep 26;347(13):966-7. doi: 10.1056/NEJMp020096.
7
Xigris: reducing mortality in adult patients with severe sepsis.Xigris：降低成年重症脓毒症患者的死亡率
Urol Nurs. 2002 Jun;22(3):200-1.
8
Management of sepsis.脓毒症的管理
N Engl J Med. 2007 Mar 15;356(11):1179; author reply 1181-2.
9
Targeting the coagulation cascade in sepsis: did we find the "magic bullet"?针对脓毒症中的凝血级联反应：我们找到“神奇子弹”了吗？
Crit Care Med. 2003 Jan;31(1):310-1. doi: 10.1097/00003246-200301000-00051.
10
New mode of intervention in sepsis treatment.脓毒症治疗的新干预模式。
Drug Discov Today. 2003 Jul 15;8(14):610-2. doi: 10.1016/s1359-6446(03)02775-2.
引用本文的文献
1
Six subphenotypes in septic shock: Latent class analysis of the PROWESS Shock study.六种败血症性休克亚型：PROWESS 休克研究的潜在类别分析。
J Crit Care. 2018 Oct;47:70-79. doi: 10.1016/j.jcrc.2018.06.012. Epub 2018 Jun 8.
2
Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients.人重组蛋白C用于成人和儿童患者的严重脓毒症及脓毒性休克。
Cochrane Database Syst Rev. 2012 Dec 12;12(12):CD004388. doi: 10.1002/14651858.CD004388.pub6.
3
Recombinant human activated protein C for severe sepsis in neonates.重组人活化蛋白C用于新生儿严重脓毒症
Cochrane Database Syst Rev. 2012 Apr 18;2012(4):CD005385. doi: 10.1002/14651858.CD005385.pub3.
4
Unblinding plan of PROWESS-SHOCK trial.PROWESS-SHOCK试验的揭盲计划。
Intensive Care Med. 2011 Aug;37(8):1384-5. doi: 10.1007/s00134-011-2272-7. Epub 2011 Jun 21.
5
Biomarkers in acute lung injury: insights into the pathogenesis of acute lung injury.急性肺损伤的生物标志物：急性肺损伤发病机制的研究进展。
Crit Care Clin. 2011 Apr;27(2):355-77. doi: 10.1016/j.ccc.2010.12.005.
本文引用的文献
1
A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis.TAK-242 治疗严重脓毒症的随机、双盲、安慰剂对照试验。
Crit Care Med. 2010 Aug;38(8):1685-94. doi: 10.1097/CCM.0b013e3181e7c5c9.
2
The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis.拯救脓毒症运动：以严重脓毒症为目标的基于国际指南的绩效改进计划的结果。
Intensive Care Med. 2010 Feb;36(2):222-31. doi: 10.1007/s00134-009-1738-3. Epub 2010 Jan 13.
3
Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis.依洛珠单抗四钠（E5564）治疗严重脓毒症患者的 2 期临床试验。
Crit Care Med. 2010 Jan;38(1):72-83. doi: 10.1097/CCM.0b013e3181b07b78.
4
Why publish statistical analysis plans?为什么要发布统计分析计划？
Crit Care Resusc. 2009 Mar;11(1):5-6.
5
Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock.一项关于活化蛋白C用于持续性感染性休克的多国安慰剂对照试验的设计、实施、分析及报告。
Intensive Care Med. 2008 Nov;34(11):1935-47. doi: 10.1007/s00134-008-1266-6. Epub 2008 Oct 7.
6
Bench-to-bedside review: the evaluation of complex interventions in critical care.从实验室到临床的综述：危重症中复杂干预措施的评估
Crit Care. 2008;12(2):210. doi: 10.1186/cc6849.
7
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.拯救脓毒症运动：严重脓毒症和脓毒性休克治疗国际指南：2008年版
Crit Care Med. 2008 Jan;36(1):296-327. doi: 10.1097/01.CCM.0000298158.12101.41.
8
Efficacy and safety of recombinant human activated protein C for severe sepsis.重组人活化蛋白C治疗严重脓毒症的疗效与安全性
N Engl J Med. 2001 Mar 8;344(10):699-709. doi: 10.1056/NEJM200103083441001.
Zotero 插件